Holen Sie sich die Stockscreener-App
62.38
1.35%
0.83
Handel nachbörslich:
60.57
-1.81
-2.90%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$61.55
Offen:
$61.73
24-Stunden-Volumen:
2.32M
Relative Volume:
0.77
Marktkapitalisierung:
$8.74B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-44.88
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
-3.50%
1M Leistung:
-5.38%
6M Leistung:
+250.45%
1J Leistung:
+235.92%
1-Tages-Spanne:
$61.17
$63.13
1-Wochen-Bereich:
$60.34
$68.44
52-Wochen-Spanne:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
62.38 | 8.62B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Equities Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business - 富途牛牛
Understanding the Setup: (ARWR) and Scalable Risk - Stock Traders Daily
ARWR: Strong Start for REDEMPLO Commercialization - Smartkarma
ARWR: Strong Start for REDEMPLO Commercialization… - Yahoo Finance
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Arrowhead Pharma (ARWR) Receives Buy Rating from HC Wainwright | - GuruFocus
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views - Benzinga
Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026 - Meyka
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR) - TechStock²
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Arrowhead Pharma stock outlook: Goldman Sachs sees 2026 catalysts ahead - Investing.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) added to S&P 400Biotechnology - marketscreener.com
Top Pharmaceutical Stocks To Follow TodayFebruary 8th - MarketBeat
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026 - TipRanks
Best Pharmaceutical Stocks To Add to Your WatchlistFebruary 7th - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return - Yahoo Finance
Principal Financial Group Inc. Buys 157,035 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Challenges Bearish Narratives On Earnings Quality - Sahm
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript - Insider Monkey
Arrowhead gains approval of Redemplo in China for high triglycerides - MSN
More Rivalry With Ionis In A Potentially ‘Transformational’ Year For Arrowhead - Citeline News & Insights
Arrowhead’s RNAi Platform Shifts Toward Commercialization And Broader Partnerships - Sahm
Arrowhead Pharmaceuticals (ARWR) Reports Strong Q1 2026 Performa - GuruFocus
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results - BioSpace
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | Arrowhead Pharmaceuticals(ARWR.US) Q1 2026 Earnings Conference - 富途牛牛
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highl - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Arrowhead Pharmaceuticals beats Q1 2026 EPS forecast - Investing.com India
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript - The Globe and Mail
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results - MarketBeat
Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M - marketscreener.com
Arrowhead (ARWR) Set to Join S&P 400 Index - GuruFocus
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 - Yahoo Finance
Is Arrowhead Pharmaceuticals (ARWR) Pricing Reflect Recent RNAi Progress And Strong Share Price Gains? - Sahm
Trading Action: Is Arrowhead Pharmaceuticals Inc gaining market share2025 Institutional Moves & Low Risk Entry Point Tips - baoquankhu1.vn
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial - Yahoo Finance
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Arrowhead Pharmaceuticals (ARWR) Valuation After First Human Dosing Of Dual Gene RNAi Therapy For Mixed Hyperlipidemia - Sahm
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following First Dual-Gene RNAi Cardio Trial Initiation - Sahm
The Technical Signals Behind (ARWR) That Institutions Follow - Stock Traders Daily
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - MSN
Arrowhead Pharmaceuticals, Inc. $ARWR is Privium Fund Management B.V.'s 9th Largest Position - MarketBeat
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
Can Arrowhead Pharmaceuticals Inc. weather a recessionJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Mfd.ru
Is Arrowhead Pharmaceuticals Inc. stock a buy or sellLayoff News & Precise Swing Trade Entry Alerts - mfd.ru
How cyclical is Arrowhead Pharmaceuticals Inc.’s revenue stream2025 Valuation Update & Scalable Portfolio Growth Ideas - Mfd.ru
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Thursday - MarketBeat
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrowhead Pharmaceuticals Inc-Aktie (ARWR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer |
Jan 05 '26 |
Sale |
63.11 |
40,164 |
2,534,661 |
171,958 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 02 '26 |
Sale |
66.10 |
13,187 |
871,703 |
3,792,739 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):